{"": [68, 1905, 0], "1. Introduction": [1906, 6757, 0], "2.1. Cell and Virus": [6770, 7174, 0], "2.2. Facility and Ethics Statement": [7175, 7589, 0], "2.3. Animals": [7590, 8937, 0], "2.4. Virus Titration": [8938, 9472, 0], "2.5. Preparation of the Inactivated SARS-CoV-2 Vaccine": [9473, 10905, 0], "2.6. Analysis of Viral Antigen": [10906, 11167, 0], "2.7. Animal Studies": [11168, 13339, 0], "2.8. RNA Extraction and SARS-CoV-2 Viral RNA Quantification by RT\u2013qPCR": [13340, 14164, 0], "2.9. Virus Isolation from Clinical Samples": [14165, 14933, 0], "2.10. ELISA": [14934, 16525, 0], "2.11. Micro Neutralization Test (MNT)": [16526, 16898, 0], "2.12. ELISPOT Assay": [16899, 17936, 0], "2.13. Repeated Dose Toxicity": [17937, 20281, 0], "2.14. Statistical Analysis": [20282, 21321, 0], "2. Methods": [6758, 21321, 1], "3.1. Generation of ERUCoV-VAC as a Vaccine Platform": [21334, 24349, 0], "3.2. ERUCoV-VAC Induces Humoral Immune Responses in Old and Young BALB/c Mice": [24350, 26382, 0], "3.3. ERUCoV-VAC Protects K18-hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Challenge": [26383, 29574, 0], "3.4. ERUCoV-VAC Reduces Upper Respiratory Tract SARS-CoV-2 Infection in Ferrets": [29575, 32377, 0], "3. Results": [21322, 32377, 1], "4. Discussion": [32378, 44227, 0], "5. Conclusions": [44228, 45204, 0]}